INGGRIS, Roda Duniawi – Seven people have died in the UK from unusual blood clots after getting the Oxford-AstraZeneca vaccine.
The deaths of the seven people were confirmed by the UK’s drug regulator, the MHRA told the BBC.
As reported by the BBC on Saturday (3/4/2021), in total, 30 people out of 18 million people who had been vaccinated until 24 March experienced this blood clot. It remains unclear whether it was just a coincidence or a real side effect of the vaccine.
The Health and Drug Products Regulatory Agency (MHRA) said the benefits continued to outweigh any risks. However, concerns have led to other countries including Germany, France, the Netherlands and Canada restricting the use of vaccines only to the elderly.
Data released by the MHRA on Friday (2/4/2021) local time showed 22 cases of cerebral venous sinus thrombosis (CVST) which is one type of blood clotting in the brain.
It is accompanied by low levels of platelets, which help the formation of blood clotting, in the body. The MHRA also found other clotting problems in addition to low platelet levels in eight people.
Now the MHRA has confirmed, via email to the BBC, that “sadly seven people have died.”
Dr June Raine, chief executive of the MHRA, said: “The benefits … in preventing COVID-19 infection and its complications continue to outweigh the risks and the public should continue to get their vaccines when invited to do so.”
An investigation is underway to determine whether the AstraZeneca vaccine caused such a rare blood clot. Earlier this week, the European Medicines Agency said it was “not proven, but possible.”
There are two problems that arouse suspicion. The first is the unusual properties of clots, including low levels of platelets and rare antibodies in the blood that have been linked to other clotting disorders.
“This increases the likelihood that vaccines can be a causal factor in these rare and unusual cases of CVST, although we don’t yet know this, so more research is needed,” said Prof David Werring, of the UCL Institute of Neurology. (*)